Abstract:Abstract BACKGROUND Immunotherapeutic strategies have largely failed for glioblastoma , the most frequent primary brain tumor. Beyond apoptosis and autophagy, little is known about cell death mechanisms in glioblastoma, despite their potential impact on the immune microenvironment. Pyroptosis, unlike apoptosis, is an immunogenic and lytic type of programmed cell death, where gasdermin proteins form pores into the plasma membrane, releasing cell content to the tumor microenvironment. Gasdermin E (GSDME), often inactivated in cancers by mutations/low expression, is proteolytically cleaved by caspase-3 upon apoptotic stimuli leading to a shift from apoptosis to pyroptosis. Here, we investigated the relevance of GSDME-mediated pyroptosis for glioblastoma. According to The Cancer Genome Atlas, GSDME is highly expressed in glioblastomas compared to many other cancers and no mutations are found. MATERIAL AND METHODS Using the drug raptinal to induce apoptosis, we assessed expression of full length and cleaved GSDME as well as cleaved caspase-3 in syngeneic mouse and human patient-derived glioblastoma stem-like cell lines by western blotting. Lytic cell death and viability were measured by lactate dehydrogenase (LDH) and WST-1 assays respectively. PI uptake assay was performed to capture pyroptotic morphology by Incucyte®️ S3. BAPTA-AM, a fast Ca2+ chelator, was used to block plasma membrane repair in human glioblastoma cell lines and analyze its effect on pyroptosis. GSDME was knocked out by CRISPR/Cas9. RESULTS GSDME and caspase-3 cleavage were confirmed after raptinal treatment in mouse and human glioblastoma cell lines, indicating that the molecular pyroptotic machinery is intact. A significant drop in viability with raptinal was shown indicating successful execution of cell death. A significant LDH release was detected in mouse glioblastoma cell lines, which could be blocked by GSDME knockout. In contrast, human glioblastoma cells, although executing GSDME cleavage, showed less or no LDH release. Pyroptotic morphology was detected after raptinal treatment in mouse glioblastoma cell lines, while it was delayed/inhibited in human glioblastoma cells. Application of BAPTA-AM in human glioblastoma cell lines enhanced pyroptotic morphology, indicating a role for plasma membrane repair in inhibiting pyroptosis. CONCLUSION The molecular machinery to execute pyroptosis is functioning in mouse and human glioblastoma cells. However, while mouse glioblastoma cells show clear execution of pyroptosis upon apoptosis induction, human glioblastoma cells indicate less efficient pyroptotic ability which partly can be reverted by blocking plasma membrane repair. While pyroptosis can induce anti-tumor immunity in experimental cancer models, future in vivo experiments must delineate if pyroptosis is a viable strategy for immunotherapy of glioblastoma.

Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate

Caspase 3/Gsdme-Dependent Pyroptosis Contributes to Chemotherapy Drug-Induced Nephrotoxicity.

Caspase‐3‐mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway

Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX/GSDME pathway

Gasdermins and pannexin-1 mediate pathways of chemotherapy-induced cell lysis in hematopoietic malignancies

The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer

Gasdermin-mediated Pyroptosis Confers Anticancer Immunity

Mechanism and regulation of pyroptosis-mediated in cancer cell death

Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin

The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis

The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles

P06.02.B GSDME-MEDIATED PYROPTOSIS IN GLIOBLASTOMA

PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage

GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity.

Targeted Pyroptosis Is a Potential Therapeutic Strategy for Cancer

The natural compound from Garcinia bracteata mainly induces GSDME-mediated pyroptosis in esophageal cancer cells

Inhibition of Caspase-3-mediated GSDME-derived Pyroptosis Aids in Noncancerous Tissue Protection of Squamous Cell Carcinoma Patients During Cisplatin-Based Chemotherapy.

Progress in the study of molecular mechanisms of cell pyroptosis in tumor therapy

Bioinspired Nano‐Photosensitizer‐Activated Caspase‐3/GSDME Pathway Induces Pyroptosis in Lung Cancer Cells

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells